Skip to search formSkip to main contentSkip to account menu

cenicriviroc

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

TAK-652

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Clinical significance of chemokine receptor antagonists
ABSTRACT Introduction: Chemokine receptors are important therapeutic targets for the treatment of many human diseases. This study… 
Highly Cited
2019
Highly Cited
2019
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver…
Review
2018
Review
2018
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
ABSTRACT Introduction: Nonalcoholic fatty liver disease (NAFLD) has an increasing prevalence worldwide. At present, no specific… 
2018
2018
Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver… 
Review
2018
Review
2018
T Cells in Adipose Tissue in Aging
Similar to obesity, aging is associated with visceral adiposity and insulin resistance. Inflammation in adipose tissue, mainly… 
2018
2018
Cenicriviroc inhibits trans‐endothelial passage of monocytes and is associated with impaired E‐selectin expression
Incidences of cardiovascular diseases (CVD) are high among virologically suppressed HIV‐infected individuals. Monocyte activation… 
Highly Cited
2016
Highly Cited
2016
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Highly Cited
2016
Highly Cited
2016
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Objective:To compare the efficacy, safety, and anti-inflammatory effects of cenicriviroc (CVC), an oral, once-daily C-C chemokine… 
2016
2016
Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
Cenicriviroc, a dual CCR2/CCR5 antagonist, is being evaluated for treatment of nonalcoholic steatohepatitis and liver fibrosis… 
Review
2013
Review
2013
HIV-1 entry inhibitors: recent development and clinical use.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)